Heart clinical trials

Explore recruiting heart clinical trials.

Recruiting heart studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Heart trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus-negative myocarditis or inflammatory cardiomyopathy (IMPROVE-MC).

Poland

Therapeutic use (Phase IV) EU CTIS Study details

MEMENTO-A Phase 3b/4 Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to assess the impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging (CMR)

Hungary, Finland, Spain, France, Greece, Italy +5 more

Phase III and phase IV (Integrated) EU CTIS Study details

A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)

Spain, Netherlands, Denmark, France, Belgium, Czechia +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Corticotrophin Releasing Factor 2 Agonist For the Treatment of Worsening Heart Failure (WHF) – The CRAFT-WHF Study

Czechia, Spain, Romania, Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study Evaluating the Long-term Efficacy and Safety of Ralinepag in Subjects with PAH via an Open-label Extension (ADVANCE-Extension)

Netherlands, Spain, Hungary, Bulgaria, Greece, France +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

(ASK-CHF2-CS201) A Phase 2, adaptive, double-blinded, placebo-controlled, randomized, multi-center trial to evaluate the efficacy, safety and tolerability of intracoronary infusion of AB-1002 in adult subjects with New York Heart Association (NYHA) Class III heart failure and non-ischemic cardiomyopathy

Austria, Spain, Germany, Netherlands, Hungary, Belgium +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Heart trials by city

Heart in Toronto Heart in Vancouver Heart in Montreal Heart in Calgary Heart in Edmonton Heart in Ottawa Heart in Winnipeg Heart in Quebec City Heart in Hamilton Heart in Kitchener Heart in London Heart in Halifax Heart in New York Heart in Los Angeles Heart in Chicago Heart in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease